CFO
MRNA icon

CVA Family Office’s Moderna MRNA Stock Holding History

CVA Family Office’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Sell
1,693
-8
-0.5% -$414 0.01% 441
2026
Q1 		$86.4K Buy
1,701
+225
+15% +$10.5K 0.01% 486
2025
Q4 		$43.5K Buy
1,476
+1,365
+1,230% +$37.1K 0.01% 570
2025
Q3 		$2.87K Sell
111
-19
-15% -$530 ﹤0.01% 957
2025
Q2 		$3.59K Sell
130
-11
-8% -$290 ﹤0.01% 928
2025
Q1 		$4K Sell
141
-403
-74% -$14.3K ﹤0.01% 927
2024
Q4 		$22.6K Buy
544
+537
+7,671% +$25.7K ﹤0.01% 655
2024
Q3 		$468 Sell
7
-534
-99% -$49K ﹤0.01% 1233
2024
Q2 		$64.2K Buy
541
+96
+22% +$12.1K 0.01% 443
2024
Q1 		$47.4K Buy
445
+315
+242% +$31.8K 0.01% 501
2023
Q4 		$12.9K Buy
+130
New +$10.9K ﹤0.01% 684
2023
Q3 		– Sell
-280
Closed -$34K – 679
2023
Q2 		$34K Sell
280
-10
-3% -$1.33K 0.01% 519
2023
Q1 		$44.5K Sell
290
-65
-18% -$10.7K 0.01% 461
2022
Q4 		$63.8K Sell
355
-40
-10% -$6.54K 0.02% 366
2022
Q3 		$47K Buy
395
+10
+3% +$1.52K 0.01% 384
2022
Q2 		$55K Buy
385
+75
+24% +$10.7K 0.02% 351
2022
Q1 		$53K Buy
310
+25
+9% +$4.21K 0.01% 386
2021
Q4 		$72K Buy
+285
New +$83.3K 0.02% 298
2021
Q1 		– Sell
-400
Closed -$42K – 783
2020
Q4 		$42K Buy
+400
New +$40.5K 0.03% 210
2020
Q3 		– Sell
-1,400
Closed -$90K – 363
2020
Q2 		$90K Buy
1,400
+400
+40% +$21.9K 0.07% 122
2020
Q1 		$30K Buy
+1,000
New +$23K 0.03% 173

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

CVA Family Office's MRNA Position: Q2 2026 in Review

CVA Family Office reduced its Moderna (MRNA) stake by 0.47% in Q2 2026, selling an estimated $414 and leaving 1,693 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #441.

CVA Family Office first reported a position in MRNA in Q1 2020 and has held it in 21 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • CVA Family Office held 1,693 shares of Moderna worth $119K as of Q2 2026.
  • CVA Family Office sold 8 Moderna shares in Q2 2026, an estimated $414.
  • Moderna made up 0.01% of CVA Family Office's portfolio in Q2 2026, its #441 holding.
  • CVA Family Office first reported a position in Moderna in Q1 2020 and has held it in 21 quarters since.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.